IgSF CAM Cytosolic Tail Modulation via GPCR Co-Localization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of Immunoglobulin Superfamily Cell Adhesion Molecules (IgSF CAMs) focuses primarily on their extracellular domains, with the functions of their cytosolic tails being poorly understood, particularly in ligand-independent activation mechanisms mediated by co-located G Protein-Coupled Receptors (GPCRs) like AT1R, which are crucial for signaling pathways involved in inflammation, oxidative stress, and cellular proliferation.
Innovation Solution
The identification of modulators, such as analogues, fragments, or derivatives of IgSF CAMs or RAGE, that can selectively modulate the ligand-independent activation of IgSF CAMs and RAGE by co-located GPCRs, specifically targeting the cytosolic tails to induce downstream signaling, including NFκB activation, independent of the ligand-binding ectodomain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If current understanding focuses primarily on extracellular domains of IgSF CAMs, then structural characterization is achieved, but functional understanding of cytosolic tail signaling is insufficient
Solution Approach 1:
The invention extracts and isolates the cytosolic tail domain of IgSF CAMs from the full-length protein, demonstrating that this isolated domain is sufficient to mediate ligand-independent signaling when co-expressed with activated GPCRs. This extraction approach reveals the specific functional role of the cytosolic tail without requiring the complex extracellular domains.
Solution Approach 2:
The invention segments the IgSF CAM protein into distinct functional domains (extracellular, transmembrane, cytosolic tail) and independently characterizes the signaling capability of each segment. The cytosolic tail is shown to function as an independent signaling unit that can interact with downstream effectors like NFκB without requiring ligand binding to the extracellular domain.
2Adaptability or versatility
If ligand-independent activation mechanisms are investigated, then new signaling pathways are discovered, but the requirement for co-located GPCRs increases system complexity
Solution Approach 1:
The invention merges the signaling functions of two previously distinct systems: IgSF CAMs (known for adhesion) and GPCRs (known for ligand-sensitive signaling). By demonstrating that co-expressed, activated GPCRs can directly activate IgSF CAM cytosolic tails without ligands, the invention creates a hybrid signaling mechanism that combines elements of both pathways.
Solution Approach 2:
The cytosolic tail of the IgSF CAM acts as an intermediary component that receives activation signals from co-located GPCRs and transmits them to downstream signaling effectors. This intermediary role allows the cytosolic tail to bridge the GPCR activation event and the downstream inflammatory signaling cascade.
3Adaptability or versatility
If cytosolic tail signaling is targeted for modulation, then therapeutic opportunities arise, but modulator specificity and selectivity become more difficult to achieve
Solution Approach 1:
The invention applies local quality by developing modulators that specifically target the cytosolic tail domain of IgSF CAMs rather than the entire protein. This localized targeting approach allows for greater selectivity, as the modulators interact with specific amino acid sequences and structural features of the cytosolic tail that are distinct from other cellular proteins.
Solution Approach 2:
Instead of targeting the traditional ligand-binding extracellular domain of IgSF CAMs, the invention inverts the approach by targeting the cytosolic tail domain. This inversion reveals a previously unrecognized therapeutic entry point that can modulate signaling without affecting cell adhesion functions mediated by the extracellular domain.
Data Source
AI summary
The invention relates to modulators of activation of Immunoglobulin Superfamily Cell Adhesion Molecules (IgSF CAMs) and modulators of activation of Receptor for Advanced Glycation End Products (RAGE) as well as screening assays for identifying modulators of activation of molecules associated with certain diseases and/or conditions in which IgSF CAMs and/or RAGE are implicated, and to medicaments and methods of treatment comprising administration of such modulators.